{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:00:56Z","timestamp":1793779256586,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-71231-7","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:42:51Z","timestamp":1735324971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world"],"prefix":"10.1038","volume":"14","author":[{"given":"Minjung","family":"Bak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ah","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kina","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heayoung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Oh","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"71231_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk, G. D. & Verma, S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review. JACC Basic Transl. Sci. 5, 632\u2013644 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"71231_CR2","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi, S. & Verges, B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 40, S28\u2013S34 (2014).","journal-title":"Diabetes Metab."},{"key":"71231_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","volume":"28","author":"Writing Committee Members, ACC AHA Joint Committee Members","year":"2022","unstructured":"Writing Committee Members, ACC AHA Joint Committee Members. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J. Card. Fail. 28, e1\u2013e167 (2022).","journal-title":"J. Card. Fail."},{"key":"71231_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"71231_CR5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","volume":"23","author":"G Savarese","year":"2021","unstructured":"Savarese, G. et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden). Eur. J. Heart Fail. 23, 1499\u20131511 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"71231_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"71231_CR7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/0735-1097(95)00012-S","volume":"25","author":"SL Olsen","year":"1995","unstructured":"Olsen, S. L. et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J. Am. Coll. Cardiol. 25, 1225\u20131231 (1995).","journal-title":"J. Am. Coll. Cardiol."},{"key":"71231_CR8","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","volume":"94","author":"MR Bristow","year":"1996","unstructured":"Bristow, M. R. et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94, 2807\u20132816 (1996).","journal-title":"Circulation"},{"key":"71231_CR9","first-page":"2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer, M. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Gr. Circ. 100, 2312\u20132318 (1999).","journal-title":"ATLAS Study Gr. Circ."},{"key":"71231_CR10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","volume":"374","author":"MA Konstam","year":"2009","unstructured":"Konstam, M. A. et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet 374, 1840\u20131848 (2009).","journal-title":"Lancet"},{"key":"71231_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00228-021-03210-0","volume":"78","author":"E Corrado","year":"2022","unstructured":"Corrado, E. et al. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. Eur. J. Clin. Pharmacol. 78, 19\u201325 (2022).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"71231_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","volume":"393","author":"BP Halliday","year":"2019","unstructured":"Halliday, B. P. et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): An open-label, pilot, randomised trial. Lancet 393, 61\u201373 (2019).","journal-title":"Lancet"},{"key":"71231_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer, M. et al. Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure. Circulation 148, 1011\u20131022 (2023).","journal-title":"Circulation"},{"key":"71231_CR14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"71231_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"71231_CR16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"71231_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","volume":"22","author":"A Goldman","year":"2023","unstructured":"Goldman, A. et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265 75\u00a0years): A retrospective, pharmacovigilance study. Cardiovasc. Diabetol. 22, 16 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"71231_CR18","doi-asserted-by":"publisher","first-page":"e026187","DOI":"10.1161\/JAHA.122.026187","volume":"11","author":"CH Garred","year":"2022","unstructured":"Garred, C. H. et al. Adherence and discontinuation of optimal heart failure therapies according to age: A Danish nationwide study. J. Am. Heart Assoc. 11, e026187 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"71231_CR19","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang, J., Ye, L., Yan, Q., Zhang, X. & Wang, L. Effects of sodium\u2013glucose cotransporter 2 inhibitors on water and sodium metabolism. Front. Pharmacol. 13, 800490 (2022).","journal-title":"Front. Pharmacol."},{"key":"71231_CR20","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","volume":"38","author":"T Heise","year":"2016","unstructured":"Heise, T. et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin. Ther. 38, 2248\u20132264 (2016).","journal-title":"Clin. Ther."},{"key":"71231_CR21","doi-asserted-by":"publisher","first-page":"e007046","DOI":"10.1161\/JAHA.117.007046","volume":"7","author":"CS Wilcox","year":"2018","unstructured":"Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R. & Griffen, S. C. Interaction between the sodium\u2013glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J. Am. Heart Assoc. 7, e007046 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"71231_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","volume":"37","author":"EMPA-KIDNEY Collaborative Group","year":"2022","unstructured":"EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol. Dial. Transplant. 37, 1317\u20131329 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"71231_CR23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"71231_CR24","first-page":"e12486","volume":"13","author":"M Shankar","year":"2021","unstructured":"Shankar, M., Narasimhappa, S. & Madhura, N. S. Urinary tract infection in chronic kidney disease population: A clinical observational study. Cureus 13, e12486 (2021).","journal-title":"Cureus"},{"key":"71231_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-021-08451-x","volume":"21","author":"N Balmaceda","year":"2021","unstructured":"Balmaceda, N. et al. Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21, 730 (2021).","journal-title":"BMC Cancer"},{"key":"71231_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3904\/kjim.2020.120","volume":"35","author":"JJ Park","year":"2020","unstructured":"Park, J. J. & Choi, D. J. Current status of heart failure: Global and Korea. Korean J. Intern. Med. 35, 487\u2013497 (2020).","journal-title":"Korean J. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71231-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T19:06:12Z","timestamp":1735326372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71231"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71231-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30653"}}